Mankind Pharma
Mankind Pharma Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Anti-infective segment expected to grow quarter-on-quarter as team stability and doctor relationships improve, despite past underperformance. Mankind Pharma expects consistent quarter-on-quarter growth in anti-infectives going forward after a correction phase of 15-18 months.
From Mankind Pharma's Q3 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Anti-infective segment expected to grow quarter-on-quarter as team stability and doctor relationships improve, despite past underperformance.
- Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth.
- Chronic and other non-acute therapies show strong quarter-on-quarter growth of 12-15%, outperforming industry averages.
- Export business grew 14% YoY in Q3 and 51% in 9 months, with EU GMP certification enhancing capabilities.
- OTC business saw improved performance with 5.2% YoY growth in Q3 and 5.6% in 9 months; modern trade and e-commerce channels growing 30-40%.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Mankind Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company's incremental capex spend for the quarter was under INR 200 crores.
- Total capex spend for 9 months FY'26 was around this band (under INR 200 crores).
- There is an ongoing facility build-up at Vadodara, leading to classification of surplus land from the BSV Hyderabad facility, which is planned to be returned to authorities.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Mankind Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Mankind Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.4K Cr, net profit ₹559 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Mankind Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Mankind Pharma Q3 FY26 results?
Anti-infective segment expected to grow quarter-on-quarter as team stability and doctor relationships improve, despite past underperformance. Mankind Pharma expects consistent quarter-on-quarter growth in anti-infectives going forward after a correction phase of 15-18 months.
What is Mankind Pharma share price analysis?
Mankind Pharma currently shows a neutral. The stock trades at a P/E of 46.2 with a market cap of ₹98,458 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mankind Pharma planning capital expenditure?
The company's incremental capex spend for the quarter was under INR 200 crores.
Keep Mankind Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.